Table 7.
Cox regression analysis of PFS
| PFS | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Variable | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P |
| Gender Male vs. Female |
0.95 (0.47–1.88) | 0.87 | ||
| Age (years), median, range < 75 vs. ≥ 75 | 0.59 (0.29–1.17) | 0.13 | 0.33 (0.15–0.72) | 0.005 |
| Performance status 0–1 vs. 2–3 | 2.09 (1.01–4.30) | 0.046 | 2.49 (1.14–5.43) | 0.022 |
| EGFR genotype | 1.88 (0.95–3.72) | 0.07 | 2.83 (1.32–6.06) | 0.007 |
| Exon 19 deletion | ||||
| L858R point mutation | ||||
| Smoking status | 1.24 (0.62–2.48) | 0.54 | ||
| Current smoker | ||||
| Never or former light smoker | ||||
| Stage | 1.66 (0.64–4.33) | 0.30 | ||
| Postoperative recurrence | ||||
| Stage IV | ||||
| Brain metastasis | 2.06 (1.05–4.05) | 0.036 | Excluded | |
| Positive vs. Negative | ||||
| Number of prior regimens | 2.03 (1.03–4.00) | 0.041 | Excluded | |
| 0 vs. ≥ 1 | ||||
| BSA | 0.88 (0.45–1.70) | 0.70 | ||
| < 1.51 vs. ≥ 1.51 | ||||
| BMI | 0.75 (0.39–1.45) | 0.39 | ||
| < 21.5 vs. ≥ 21.5 | ||||
BMI, body mass index; BSA, body surface area; CI, confidence interval; PFS, progression‐free survival.